Because arginine vasotocin (AVT) activates male sexual behaviors in the rough-skinned newt (Taricha granulosa), quantitative autoradiography with radiolabelled arginine vasopressin (3H-AVP) was used to characterize putative AVT receptors in the telencephalon of this amphibian. Analyses were restricted to specific binding sites in the medial pallium, although dense binding also was observed in the dorsal pallium and amygdala pars lateralis. Binding of 3H-AVP to these sites was saturable, specific, reversible, of high affinity (Kd= 1 nM) and low capacity (57 fmol/mg protein). The rank order of potency of related peptides in inhibiting 3H-AVP binding was as follows: AVT > d(CH2)5[Tyr(Me)2]AVP (a mammalian pressor antagonist) > AVP, oxytocin, and [dPen1Tyr(Me)2]AVP (also a pressor antagonist) > mesotocin ≫ desGly(NH2)AVP, AVP fragment 4–9 and pressinoic acid. Thus, these binding sites appear to represent authentic central nervous system receptors for AVT. Furthermore, ligand specificity for the binding sites in this amphibian differ from that reported for AVP binding sites in rat brains. The AVT receptors in the medial pallium, dorsal pallium, and amygdala pars lateralis may represent site(s) of action where AVT elicits sexual behaviors in male T. granulosa.

Keywords:
Arginine vasotocin receptors, Amphibian brain, Rough-skinned newt
This content is only available via PDF.
© 1988 S. Karger AG, Basel
1988
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.